Immix Biopharma (IMMX) Long-Term Debt Issuances (2021)

Immix Biopharma (IMMX) reported Long-Term Debt Issuances of $100000.0 for Q2 2021, little changed sequentially from $100000.0 in Q1 2021.

Immix Biopharma (IMMX) Long-Term Debt Issuances (2021) Analysis & Trends

Immix Biopharma (IMMX) has 1 years of Long-Term Debt Issuances data on file, last reported at $100000.0 in Q2 2021.

For the quarter ending Q2 2021, Long-Term Debt Issuances changed N/A year-over-year to $100000.0; the trailing twelve-month figure through Sep 2022 stood at $100000.0 (changed N/A YoY), and the FY2022 full-year result was $50000.0, down 75.0% from the prior year.
Long-Term Debt Issuances held at $100000.0 in Q2 2021, from $100000.0 in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $100000.0 in Q1 2021 to a low of $100000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Immix Biopharma	487.25 Mn	487.25 Mn	-	-

Download Data